Bevacizumab--current status and future directions.
Angiogenesis is crucial to tumour initiation, survival and metastasis. Vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors in cancer development. Bevacizumab (a humanised monoclonal antibody against VEGF) has a reasonable safety profile and proven efficacy i...
Main Authors: | , |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2005
|